IMRN.US Immuron Ltd ADR

Healthcare Biotechnology USA Stocks
0.8753 USD
Close of Nov 15, 2026
0.6765 1.99
Market cap
USD 7.06M
P/E
-
P/B
0.94x
ROE
-34.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is IMRN.US undervalued?

Graham number

The Graham number of Immuron Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immuron Ltd ADR fundamental analysis

No fundamental analysis for Immuron Ltd ADR yet.

Immuron Ltd ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immuron Ltd ADR

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as …

Full company profile